Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial dihydropteroate synthase

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1938

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Dermatitis herpetiformis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Whitby, L.

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

4

EPA CompTox

3

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

SULFONAMIDES AND TRIMETHOPRIM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Short-acting sulfonamides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SULFAPYRIDINE

Y5V2N1KE8U

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Dermatitis herpetiformis

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by ...

manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.

SULFAPYRIDINE CALCIUM

35HMH7A87O

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Dermatitis herpetiformis

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by ...

manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.

SULFAPYRIDINE SODIUM MONOHYDRATE

FV94Y8O7J7

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Dermatitis herpetiformis

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by ...

manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.

SULFAPYRIDINE SODIUM

H3SKB3662O

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Dermatitis herpetiformis

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by ...

manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1